GlassScriptPhysician profile
Valentina Macrinici
NPI 1154581783
$1,850.37
in general payments reported to CMS, 2019-2025
25 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.67 · 2021: $11.92 · 2022: $240 · 2023: $976 · 2024: $136 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.07 |
| Education | $181.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $235.78 | 2023 | Padcev |
| Pfizer INC. | $174.76 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $152.27 | 2023-2025 | |
| Lilly USA, LLC | $140.68 | 2022-2024 | Verzenio, Retevmo |
| Genentech USA, INC. | $121.79 | 2019-2023 | Kadcyla, Phesgo, Perjeta |
| Gilead Sciences, INC. | $117.47 | 2021-2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $109.29 | 2023-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Genzyme Corporation | $107.37 | 2025 | |
| Merck Sharp & Dohme LLC | $106.84 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $89.31 | 2022-2025 | Opdivo, Eliquis |
| Daiichi Sankyo INC. | $76.32 | 2023-2025 | Enhertu |
| Celgene Corporation | $61.47 | 2023 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $45.24 | 2022 | |
| Janssen Biotech, INC. | $41.55 | 2025 | Erleada, Balversa |
| Janssen Pharmaceuticals, INC | $37.36 | 2023 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $36.07 | 2022-2023 | Cosela |
| Array Biopharma INC | $29.83 | 2025 | Braftovi, Lorbrena, Mektovi |
| Taiho Oncology, INC. | $28.29 | 2022-2024 | |
| Mirati Therapeutics, INC. | $25.08 | 2023 | Krazati |
| Cti Biopharma Corp. | $23.50 | 2023 | Vonjo |
| Tempus Ai, INC | $23.06 | 2024 | |
| Myovant Sciences INC. | $20.98 | 2022 | |
| Puma Biotechnology, INC. | $16.97 | 2019 | |
| Karyopharm Therapeutics INC. | $15.23 | 2023 | Xpovio |
| Agios Pharmaceuticals, INC. | $13.86 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valentina Macrinici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.